{"id":45208,"date":"2022-12-07T13:51:10","date_gmt":"2022-12-07T18:51:10","guid":{"rendered":"https:\/\/reviewofmm.com\/?p=45208"},"modified":"2022-12-07T13:51:10","modified_gmt":"2022-12-07T18:51:10","slug":"kathryn-richdale-joins-coopervisions-research-and-development-team","status":"publish","type":"post","link":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/","title":{"rendered":"Kathryn Richdale Joins CooperVision’s Research and Development Team"},"content":{"rendered":"

December 7, 2022<\/strong><\/p>\n

\"\"<\/a>SAN RAMON, Calif. \u2014 Kathryn Richdale, OD, PhD, Diplomate CCLRT, has joined CooperVision’s<\/a><\/strong> growing research and development team. In her role as a Clinical Research Fellow, Dr. Richdale will work across multiple areas of CooperVision\u2019s clinical affairs on projects related to European Union Medical Device Regulation, and most timely, the ongoing MiSight 1 day clinical studies in countries around the world. Under Dr. Richdale\u2019s direction, these studies will complement CooperVision\u2019s widely cited international MiSight 1 day study<\/a><\/strong>.<\/p>\n

\u201cData from the MiSight 1 day post-approval study will help define the future of myopia control for millions of children, while simultaneously extending CooperVision\u2019s leadership in the field,\u201d said Dr. Richdale. \u201cIt\u2019s a privilege to apply my experience as an eye care professional, researcher, and educator in a new capacity to advance scientific understanding and clinical action on the international stage.\u201d<\/p>\n

Dr. Richdale has decades of clinical and research expertise in myopia, presbyopia, and cornea\/anterior segment disease management. Most recently an associate professor at the University of Houston College of Optometry, she has also held roles at the SUNY College of Optometry and Ohio State University. She received her bachelor\u2019s degree from the University of Notre Dame and her PhD, Doctor of Optometry degree, and Cornea and Contact Lens Advanced Practice Fellowship from Ohio State University. Her peer-reviewed publications<\/a><\/strong> have grown the knowledge base that eye care professionals need for evidence-based practice.<\/p>\n

In addition to the expansion, CooperVision\u2019s R&D team has continued to advance. Paul Chamberlain, BSc (Hons), has recently been promoted to Senior Director of Research Programs and has been appointed to the CooperVision R&D senior leadership team. In recent years, he has been instrumental in the research behind MiSight 1 day, leading the study analysis that would lay the foundation for FDA approval* in 2019 and garner industry acclaim with the American Academy of Optometry\u2019s Garland W. Clay Award<\/a><\/strong>\u00a0in 2021. His expanded role will now include presbyopia research oversight as well.<\/p>\n

\u201cCooperVision has invested in researching the toughest vision challenges for decades, notably myopia, foretelling the disease\u2019s global impact and how innovative interventions can change children\u2019s lives. You can see it in our research rigor, in our comprehensive myopia management portfolio, and in our growing team,\u201d said Chamberlain. \u201cTogether, we continue to build an evidence base that ECPs can trust and apply in their practice. The growing prevalence and severity of childhood myopia demands it.\u201d<\/p>\n

 <\/p>\n

*U.S. Indications for Use:<\/strong> MiSight\u00a0<\/sup>1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with \u2264 0.75 diopters of astigmatism. The lens is to be discarded after each removal<\/span><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

December 7, 2022 SAN RAMON, Calif. \u2014 Kathryn Richdale, OD, PhD, Diplomate CCLRT, has joined CooperVision’s growing research and development team. In her role as a Clinical Research Fellow, Dr. Richdale will work across multiple areas of CooperVision\u2019s clinical affairs on projects related to European Union Medical Device Regulation, and most timely, the ongoing MiSight 1 day clinical studies in countries around the world. Under Dr. Richdale\u2019s direction, these studies will complement CooperVision\u2019s widely cited international MiSight 1 day study. \u201cData from the MiSight 1 day post-approval study will help define the future of myopia control for millions of children, while simultaneously extending CooperVision\u2019s leadership in the field,\u201d said Dr. Richdale. \u201cIt\u2019s a privilege to apply my experience as an eye care professional, researcher, and educator in a new capacity to advance scientific understanding and clinical action on the international stage.\u201d Dr. Richdale has decades of clinical and research expertise in myopia, presbyopia, and cornea\/anterior segment disease management. Most recently an associate professor at the University of Houston College of Optometry, she has also held roles at the SUNY College of Optometry and Ohio State University. She received her bachelor\u2019s degree from the University of Notre Dame and her PhD, Doctor of Optometry degree, and Cornea and Contact Lens Advanced Practice Fellowship from Ohio State University. Her peer-reviewed publications have grown the knowledge base that eye care professionals need for evidence-based practice. In addition to the expansion, CooperVision\u2019s R&D team has continued to advance. Paul Chamberlain, BSc (Hons), has recently been promoted to Senior Director of Research Programs and has been appointed to the CooperVision R&D senior leadership team. In recent years, he has been instrumental in the research behind MiSight 1 day, leading the study analysis that would lay the foundation for FDA approval* in 2019 and garner industry acclaim with the American Academy of Optometry\u2019s Garland W. Clay Award\u00a0in 2021. His expanded role will now include presbyopia research oversight as well. \u201cCooperVision has invested in researching the toughest vision challenges for decades, notably myopia, foretelling the disease\u2019s global impact and how innovative interventions can change children\u2019s lives. You can see it in our research rigor, in our comprehensive myopia management portfolio, and in our growing team,\u201d said Chamberlain. \u201cTogether, we continue to build an evidence base that ECPs can trust and apply in their practice. The growing prevalence and severity of childhood myopia demands it.\u201d   *U.S. Indications […]<\/p>\n","protected":false},"author":375,"featured_media":45209,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1733],"tags":[460,2373,1420,3895,1735,2878,452,698,1067,1734,1584,1737,4194],"yoast_head":"\nKathryn Richdale Joins CooperVision's Research and Development Team - Review of Myopia Management<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kathryn Richdale Joins CooperVision's Research and Development Team - Review of Myopia Management\" \/>\n<meta property=\"og:description\" content=\"December 7, 2022 SAN RAMON, Calif. \u2014 Kathryn Richdale, OD, PhD, Diplomate CCLRT, has joined CooperVision’s growing research and development team. In her role as a Clinical Research Fellow, Dr. Richdale will work across multiple areas of CooperVision\u2019s clinical affairs on projects related to European Union Medical Device Regulation, and most timely, the ongoing MiSight 1 day clinical studies in countries around the world. Under Dr. Richdale\u2019s direction, these studies will complement CooperVision\u2019s widely cited international MiSight 1 day study. \u201cData from the MiSight 1 day post-approval study will help define the future of myopia control for millions of children, while simultaneously extending CooperVision\u2019s leadership in the field,\u201d said Dr. Richdale. \u201cIt\u2019s a privilege to apply my experience as an eye care professional, researcher, and educator in a new capacity to advance scientific understanding and clinical action on the international stage.\u201d Dr. Richdale has decades of clinical and research expertise in myopia, presbyopia, and cornea\/anterior segment disease management. Most recently an associate professor at the University of Houston College of Optometry, she has also held roles at the SUNY College of Optometry and Ohio State University. She received her bachelor\u2019s degree from the University of Notre Dame and her PhD, Doctor of Optometry degree, and Cornea and Contact Lens Advanced Practice Fellowship from Ohio State University. Her peer-reviewed publications have grown the knowledge base that eye care professionals need for evidence-based practice. In addition to the expansion, CooperVision\u2019s R&D team has continued to advance. Paul Chamberlain, BSc (Hons), has recently been promoted to Senior Director of Research Programs and has been appointed to the CooperVision R&D senior leadership team. In recent years, he has been instrumental in the research behind MiSight 1 day, leading the study analysis that would lay the foundation for FDA approval* in 2019 and garner industry acclaim with the American Academy of Optometry\u2019s Garland W. Clay Award\u00a0in 2021. His expanded role will now include presbyopia research oversight as well. \u201cCooperVision has invested in researching the toughest vision challenges for decades, notably myopia, foretelling the disease\u2019s global impact and how innovative interventions can change children\u2019s lives. You can see it in our research rigor, in our comprehensive myopia management portfolio, and in our growing team,\u201d said Chamberlain. \u201cTogether, we continue to build an evidence base that ECPs can trust and apply in their practice. The growing prevalence and severity of childhood myopia demands it.\u201d   *U.S. Indications […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/\" \/>\n<meta property=\"og:site_name\" content=\"Review of Myopia Management\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-07T18:51:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/reviewofmm.com\/wp-content\/uploads\/2022\/12\/Kathryn-Richdale-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1708\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kristen Dalli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kristen Dalli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/\",\"url\":\"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/\",\"name\":\"Kathryn Richdale Joins CooperVision's Research and Development Team - Review of Myopia Management\",\"isPartOf\":{\"@id\":\"https:\/\/reviewofmm.com\/#website\"},\"datePublished\":\"2022-12-07T18:51:10+00:00\",\"dateModified\":\"2022-12-07T18:51:10+00:00\",\"author\":{\"@id\":\"https:\/\/reviewofmm.com\/#\/schema\/person\/f943d3b48eea27bd0425746fe057dac7\"},\"breadcrumb\":{\"@id\":\"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/reviewofmm.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kathryn Richdale Joins CooperVision’s Research and Development Team\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/reviewofmm.com\/#website\",\"url\":\"https:\/\/reviewofmm.com\/\",\"name\":\"Review of Myopia Management\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/reviewofmm.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/reviewofmm.com\/#\/schema\/person\/f943d3b48eea27bd0425746fe057dac7\",\"name\":\"Kristen Dalli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/reviewofmm.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9d10679bcf35e426531ce6d2b8d0b60e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9d10679bcf35e426531ce6d2b8d0b60e?s=96&d=mm&r=g\",\"caption\":\"Kristen Dalli\"},\"url\":\"https:\/\/reviewofmm.com\/author\/kdalli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kathryn Richdale Joins CooperVision's Research and Development Team - Review of Myopia Management","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/","og_locale":"en_US","og_type":"article","og_title":"Kathryn Richdale Joins CooperVision's Research and Development Team - Review of Myopia Management","og_description":"December 7, 2022 SAN RAMON, Calif. \u2014 Kathryn Richdale, OD, PhD, Diplomate CCLRT, has joined CooperVision’s growing research and development team. In her role as a Clinical Research Fellow, Dr. Richdale will work across multiple areas of CooperVision\u2019s clinical affairs on projects related to European Union Medical Device Regulation, and most timely, the ongoing MiSight 1 day clinical studies in countries around the world. Under Dr. Richdale\u2019s direction, these studies will complement CooperVision\u2019s widely cited international MiSight 1 day study. \u201cData from the MiSight 1 day post-approval study will help define the future of myopia control for millions of children, while simultaneously extending CooperVision\u2019s leadership in the field,\u201d said Dr. Richdale. \u201cIt\u2019s a privilege to apply my experience as an eye care professional, researcher, and educator in a new capacity to advance scientific understanding and clinical action on the international stage.\u201d Dr. Richdale has decades of clinical and research expertise in myopia, presbyopia, and cornea\/anterior segment disease management. Most recently an associate professor at the University of Houston College of Optometry, she has also held roles at the SUNY College of Optometry and Ohio State University. She received her bachelor\u2019s degree from the University of Notre Dame and her PhD, Doctor of Optometry degree, and Cornea and Contact Lens Advanced Practice Fellowship from Ohio State University. Her peer-reviewed publications have grown the knowledge base that eye care professionals need for evidence-based practice. In addition to the expansion, CooperVision\u2019s R&D team has continued to advance. Paul Chamberlain, BSc (Hons), has recently been promoted to Senior Director of Research Programs and has been appointed to the CooperVision R&D senior leadership team. In recent years, he has been instrumental in the research behind MiSight 1 day, leading the study analysis that would lay the foundation for FDA approval* in 2019 and garner industry acclaim with the American Academy of Optometry\u2019s Garland W. Clay Award\u00a0in 2021. His expanded role will now include presbyopia research oversight as well. \u201cCooperVision has invested in researching the toughest vision challenges for decades, notably myopia, foretelling the disease\u2019s global impact and how innovative interventions can change children\u2019s lives. You can see it in our research rigor, in our comprehensive myopia management portfolio, and in our growing team,\u201d said Chamberlain. \u201cTogether, we continue to build an evidence base that ECPs can trust and apply in their practice. The growing prevalence and severity of childhood myopia demands it.\u201d   *U.S. Indications […]","og_url":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/","og_site_name":"Review of Myopia Management","article_published_time":"2022-12-07T18:51:10+00:00","og_image":[{"width":1708,"height":2560,"url":"https:\/\/reviewofmm.com\/wp-content\/uploads\/2022\/12\/Kathryn-Richdale-scaled.jpg","type":"image\/jpeg"}],"author":"Kristen Dalli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Kristen Dalli","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/","url":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/","name":"Kathryn Richdale Joins CooperVision's Research and Development Team - Review of Myopia Management","isPartOf":{"@id":"https:\/\/reviewofmm.com\/#website"},"datePublished":"2022-12-07T18:51:10+00:00","dateModified":"2022-12-07T18:51:10+00:00","author":{"@id":"https:\/\/reviewofmm.com\/#\/schema\/person\/f943d3b48eea27bd0425746fe057dac7"},"breadcrumb":{"@id":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/reviewofmm.com\/"},{"@type":"ListItem","position":2,"name":"Kathryn Richdale Joins CooperVision’s Research and Development Team"}]},{"@type":"WebSite","@id":"https:\/\/reviewofmm.com\/#website","url":"https:\/\/reviewofmm.com\/","name":"Review of Myopia Management","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/reviewofmm.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/reviewofmm.com\/#\/schema\/person\/f943d3b48eea27bd0425746fe057dac7","name":"Kristen Dalli","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/reviewofmm.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9d10679bcf35e426531ce6d2b8d0b60e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9d10679bcf35e426531ce6d2b8d0b60e?s=96&d=mm&r=g","caption":"Kristen Dalli"},"url":"https:\/\/reviewofmm.com\/author\/kdalli\/"}]}},"parsely":{"version":"1.1.0","meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Kathryn Richdale Joins CooperVision’s Research and Development Team","url":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/reviewofmm.com\/kathryn-richdale-joins-coopervisions-research-and-development-team\/"},"thumbnailUrl":"https:\/\/reviewofmm.com\/wp-content\/uploads\/2022\/12\/Kathryn-Richdale-100x150.jpg","image":{"@type":"ImageObject","url":"https:\/\/reviewofmm.com\/wp-content\/uploads\/2022\/12\/Kathryn-Richdale-scaled.jpg"},"articleSection":"Latest Myopia News","author":[{"@type":"Person","name":"Kristen Dalli"}],"creator":["Kristen Dalli"],"publisher":{"@type":"Organization","name":"Review of Myopia Management","logo":""},"keywords":["coopervision","coopervision misight 1 day","kathryn richdale","latest myopia news","misight 1 day","misight 1 day contact lenses","myopia","myopia control","myopia management","myopia news briefs","myopia progression","paul chamberlain","research and development"],"dateCreated":"2022-12-07T18:51:10Z","datePublished":"2022-12-07T18:51:10Z","dateModified":"2022-12-07T18:51:10Z"},"rendered":"<script type=\"application\/ld+json\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"Kathryn Richdale Joins CooperVision’s Research and Development Team\",\"url\":\"https:\\\/\\\/reviewofmm.com\\\/kathryn-richdale-joins-coopervisions-research-and-development-team\\\/\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/reviewofmm.com\\\/kathryn-richdale-joins-coopervisions-research-and-development-team\\\/\"},\"thumbnailUrl\":\"https:\\\/\\\/reviewofmm.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Kathryn-Richdale-100x150.jpg\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/reviewofmm.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Kathryn-Richdale-scaled.jpg\"},\"articleSection\":\"Latest Myopia News\",\"author\":[{\"@type\":\"Person\",\"name\":\"Kristen Dalli\"}],\"creator\":[\"Kristen Dalli\"],\"publisher\":{\"@type\":\"Organization\",\"name\":\"Review of Myopia Management\",\"logo\":\"\"},\"keywords\":[\"coopervision\",\"coopervision misight 1 day\",\"kathryn richdale\",\"latest myopia news\",\"misight 1 day\",\"misight 1 day contact lenses\",\"myopia\",\"myopia control\",\"myopia management\",\"myopia news briefs\",\"myopia progression\",\"paul chamberlain\",\"research and development\"],\"dateCreated\":\"2022-12-07T18:51:10Z\",\"datePublished\":\"2022-12-07T18:51:10Z\",\"dateModified\":\"2022-12-07T18:51:10Z\"}<\/script>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/reviewofmm.com\/p.js"},"cc_featured_image_caption":{"caption_text":"","source_text":"","source_url":""},"_links":{"self":[{"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/posts\/45208"}],"collection":[{"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/users\/375"}],"replies":[{"embeddable":true,"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/comments?post=45208"}],"version-history":[{"count":5,"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/posts\/45208\/revisions"}],"predecessor-version":[{"id":45222,"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/posts\/45208\/revisions\/45222"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/media\/45209"}],"wp:attachment":[{"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/media?parent=45208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/categories?post=45208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/reviewofmm.com\/wp-json\/wp\/v2\/tags?post=45208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}